


Figure 1. Flow chart describing the preparation of lipid/S230 (pasireotide) samples for solubility screening.




Figure 2. Injectability (seconds/mL) measured at 20N constant force as a function of formulation composition (see Table 3).




Figure 3. Injectability (seconds per mL), measured at 20N constant force, as a function of formulation viscosity .




Figure 4. Comparison of stability data on lipid/pasireotide formulations for various salts, differentiated by their respective solvent composition




Figure 5. Mean plasma concentrations (n = 6) of SOM230 (pasireotide pamoate) after s.c. injection in rats.




Figure 6. Mean plasma concentrations (n = 6) of SOM230 (pasireotide pamoate) after s.c. injection in rats.




Figure 7. Dose linearity with respect to exposure (AUC) in study PK-12-438. Error bars represent standard deviation.




Figure 8. Dose linearity with respect to Cmax in study PK-12-438. Error bars represent standard deviation.




Figure 9. Mean plasma concentrations (n = 6) of SOM230 (pasireotide pamoate) after s.c. injection in rats.




Figure 10. The SOM230 purity after storage at 5°C. The figure legend refers to the respective batch number as indicated in Table 19.




Figure 11. *The SOM230 purity after storage at 25°C/60% RH. The figure legend refers to the respective batch number as indicated in Table 19.*